Transcatheter Aortic Valve Replacement (TAVR) Clinical Trials

Clinical trials related to Transcatheter Aortic Valve Replacement (TAVR) Procedure

Patient Quality of Recovery After TAVR With Different Sedation Regimens

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The goal of this clinical trial is to learn whether the type of sedation medication used during a transcatheter aortic valve replacement (TAVR) affects how people recover after the procedure. The main question this study aims to answer is whether different sedation regimens (propofol, dexmedetomidine, or midazolam with fentanyl) lead to differences in quality of recovery on the first day after the procedure. Researchers will compare three commonly used sedation medications (propofol, dexmedetomidine, or midazolam with fentanyl) to determine whether they lead to differences in recovery following a TAVR. Participants will: * Be enrolled before their scheduled TAVR procedure * Be randomly assigned to receive one of the three sedation medications during their procedure * Complete short surveys on postoperative days 1 and 7 about pain levels, how they feel during their recovery, and how satisfied they were with their anesthesia experience

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:

• 18-90 years old, inclusive

• Undergoing transfemoral TAVR under Monitored Anesthesia Care (MAC)

• Speaks English or Spanish

• Consents to participate

Locations
United States
Illinois
Endeavor Health
RECRUITING
Glenview
Contact Information
Primary
Jessica Brickner
jessica.brickner@endeavorhealth.org
847-570-1197
Backup
Nia Moragne
nia.moragne@endeavorhealth.org
847-570-1197
Time Frame
Start Date: 2026-03-16
Estimated Completion Date: 2028-06
Participants
Target number of participants: 126
Treatments
Experimental: Propofol
Participants will receive propofol for intraoperative sedation during transcatheter aortic valve replacement (TAVR).
Experimental: Dexmedetomidine
Participants will receive dexmedetomidine for intraoperative sedation during transcatheter aortic valve replacement (TAVR).
Experimental: Midazolam and Fentanyl
Participants will receive a combination of midazolam and fentanyl for intraoperative sedation during transcatheter aortic valve replacement (TAVR).
Sponsors
Leads: David Lyubashevsky

This content was sourced from clinicaltrials.gov